海外有望企業情報OACP IE LTD

OaCP IE LTDは解剖病理学および分子診断分野の革新を目指すディープテック系ライフサイエンス企業であり、がん診断における主要なボトルネックであるハイブリダイゼーション工程の大幅短縮を実現する触媒技術を開発している。同社は特許取得済み触媒を既存試薬に組み込むことで、FISHおよびISHプロトコルを従来の一晩処理から最大2時間へ短縮可能とする。RocheおよびFunakoshiとの提携により商業的検証が進められており、既存設備のままで最大10倍の処理能力向上を実現する。また日本ではFunakoshiとの流通パートナーシップを通じて展開を開始しているほか、欧州の法的製造者としてIVDRやMDRに準拠した市場参入支援を提供する。累計100万ドル以上の収益と特許ポートフォリオを有し、産業展開に向けた段階にある。同社は日本における技術提携、OEMおよびライセンス契約、戦略投資を求めている。

OaCP IE LTD is a deep-tech life sciences company that has developed a breakthrough chemical catalyst technology designed to transform anatomical pathology and molecular diagnostics. The company aims to eliminate a major bottleneck in cancer diagnostics, namely the 24-hour hybridization cycle. By integrating its patented catalysts into standard reagent formulations, it enables Fluorescence In Situ Hybridization and In Situ Hybridization protocols to be completed within a maximum of two hours, significantly reducing the traditional overnight process. The technology has been commercially validated through partnerships with Roche and Funakoshi Co Ltd. Its plug-and-play reagents enable laboratories to increase diagnostic throughput by up to ten times using existing microscopy and imaging equipment without additional capital investment. The company is already established in the Japanese market through a distribution partnership with Funakoshi Co Ltd and has been recognized by the Tokyo Metropolitan Government Deloitte Inbound Program. As a European legal manufacturer, it provides a gateway for Japanese manufacturers to enter the EU market under the latest IVDR and MDR regulations. With cumulative revenue exceeding one million US dollars and a strong portfolio of granted patents including in India, it is positioned as a partner suitable for large-scale industrial integration. The company is seeking technical alliances, OEM and licensing agreements with Japanese probe manufacturers, and strategic investment to establish a permanent operational base in Japan and advance same-day cancer diagnostics.